NDAORALCAPSULEPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
proliferator-activated receptor (PPAR)-delta (δ) agonist. However, the mechanism by which seladelpar exerts its therapeutic effects in patients with PBC is not well understood. Pharmacological activity that is potentially relevant to therapeutic effects includes inhibition of bile acid synthesis…
Clinical Trials (1)
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Started Sep 2023
318 enrolled
Primary Biliary Cholangitis
Loss of Exclusivity
LOE Date
Mar 19, 2035
110 months away
Patent Expiry
Mar 19, 2035
Exclusivity Expiry
Aug 14, 2031